2018 Vol. 15, No. 10
Display Method:
2018, 15(10): 611-617.
doi: 10.11909/j.issn.1671-5411.2018.10.003
Abstract:
Objective To study the association between the expression of microRNA-155 (miRNA-155) in peripheral blood CD4+ T lymphocytes and the level of serum interferon-γ (IFN-γ) concentration and the severity of coronary artery disease (CAD). Methods After coronary angiography, 252 patients with suspected unstable angina pectoris (UAP) were divided into the UAP group (128 patients with CAD confirmed by angiography) and the control group (124 patients without CAD confirmed by angiography). Fresh peripheral blood was extracted 16–24 h before coronary angiography, CD4+T lymphocytes was tested using immunomagnetic beads, the expression of miRNA-155 was tested using quantitative PCR and the expression of IFN-γ was tested using enzyme-linked immunosorbent assay (ELISA). According to the results of angiography, Gensini score of coronary artery lesions was analyzed. Furthermore, we also analysis the association between the level of miRNA-155 in peripheral blood CD4+ T lymphocytes, the level of serum IFN-γ and Gensini score of coronary lesion. Results The levels of miRNA-155 (0.49 ± 0.08 vs. 0.23 ± 0.09) and IFN-γ (227.58 ± 26.01 vs. 141.23 ± 17.89) in the UAP group were significantly higher than that of the control group, the difference was statistically significant. The level of miRNA-155 and IFN-γ were positively correlated with Gensini score of CAD (r = 0.534, r= 0.713, respectively, all P r = 0.686, P Conclusions The level of miRNA-155 in peripheral blood CD4+ T lymphocytes and the level of IFN-γ are closely correlated with the severity of CAD.
Objective To study the association between the expression of microRNA-155 (miRNA-155) in peripheral blood CD4+ T lymphocytes and the level of serum interferon-γ (IFN-γ) concentration and the severity of coronary artery disease (CAD). Methods After coronary angiography, 252 patients with suspected unstable angina pectoris (UAP) were divided into the UAP group (128 patients with CAD confirmed by angiography) and the control group (124 patients without CAD confirmed by angiography). Fresh peripheral blood was extracted 16–24 h before coronary angiography, CD4+T lymphocytes was tested using immunomagnetic beads, the expression of miRNA-155 was tested using quantitative PCR and the expression of IFN-γ was tested using enzyme-linked immunosorbent assay (ELISA). According to the results of angiography, Gensini score of coronary artery lesions was analyzed. Furthermore, we also analysis the association between the level of miRNA-155 in peripheral blood CD4+ T lymphocytes, the level of serum IFN-γ and Gensini score of coronary lesion. Results The levels of miRNA-155 (0.49 ± 0.08 vs. 0.23 ± 0.09) and IFN-γ (227.58 ± 26.01 vs. 141.23 ± 17.89) in the UAP group were significantly higher than that of the control group, the difference was statistically significant. The level of miRNA-155 and IFN-γ were positively correlated with Gensini score of CAD (r = 0.534, r= 0.713, respectively, all P r = 0.686, P Conclusions The level of miRNA-155 in peripheral blood CD4+ T lymphocytes and the level of IFN-γ are closely correlated with the severity of CAD.
2018, 15(10): 618-627.
doi: 10.11909/j.issn.1671-5411.2018.10.002
Abstract:
Background Growth-differentiation factor-15 (GDF-15) is a promising prognostic biomarker in patients with chronic heart failure (CHF). Comparatively little is known about the value of repeated measurement of GDF-15 with CHF in Chinese Han population. This study sought to identify the clinical value of repeated measurement of GDF-15 in Chinese Han patients with post-myocardial infarction CHF. Methods In total, 232 consecutive Chinese Han patients with post-myocardial infarction CHF were enrolled prospectively from January 2014 to June 2016.The plasma concentration of GDF-15 was determined on admission and over 12 months. Patients were followed up for all-cause death and a composite outcome of major adverse cardiac events (MACE) included all-cause death, myocardial infarction and first heart failure (HF) re-hospitalization. Association with other clinical variables and adverse outcomes of repeated measurement of GDF-15 was explored. Results The median baseline GDF-15 level was 2025 ng/L. Baseline GDF-15 was moderately associated with baseline N-terminal pro-B type natriuretic peptide (NT-proBNP) (coefficient 0.561, P P = 0.037) and MACE (adjusted hazard ratio 2.243 per 1 Ln U, 95% CI: 1.181–1.775; P P = 0.015). In the joint model, GDF-15 was also shown to be a risk factor for all-cause death (HR = 2.749, 95% CI: 1.667–3.831; P P Conclusions Repeated measurements of GDF-15 have promising prognostic value of the risk of all-cause death in Chinese Han patients with CHF post-myocardial infarction. GDF-15 may influence the post-myocardial infarction CHF through the path physiological pathway of myocardial remodeling.
Background Growth-differentiation factor-15 (GDF-15) is a promising prognostic biomarker in patients with chronic heart failure (CHF). Comparatively little is known about the value of repeated measurement of GDF-15 with CHF in Chinese Han population. This study sought to identify the clinical value of repeated measurement of GDF-15 in Chinese Han patients with post-myocardial infarction CHF. Methods In total, 232 consecutive Chinese Han patients with post-myocardial infarction CHF were enrolled prospectively from January 2014 to June 2016.The plasma concentration of GDF-15 was determined on admission and over 12 months. Patients were followed up for all-cause death and a composite outcome of major adverse cardiac events (MACE) included all-cause death, myocardial infarction and first heart failure (HF) re-hospitalization. Association with other clinical variables and adverse outcomes of repeated measurement of GDF-15 was explored. Results The median baseline GDF-15 level was 2025 ng/L. Baseline GDF-15 was moderately associated with baseline N-terminal pro-B type natriuretic peptide (NT-proBNP) (coefficient 0.561, P P = 0.037) and MACE (adjusted hazard ratio 2.243 per 1 Ln U, 95% CI: 1.181–1.775; P P = 0.015). In the joint model, GDF-15 was also shown to be a risk factor for all-cause death (HR = 2.749, 95% CI: 1.667–3.831; P P Conclusions Repeated measurements of GDF-15 have promising prognostic value of the risk of all-cause death in Chinese Han patients with CHF post-myocardial infarction. GDF-15 may influence the post-myocardial infarction CHF through the path physiological pathway of myocardial remodeling.
2018, 15(10): 628-633.
doi: 10.11909/j.issn.1671-5411.2018.10.008
Abstract:
Objective To retrospectively identify risk factors and the prognosis for new-onset atrial fibrillation (AF) after implantation of dual-chamber pacemakers in elderly patients. Methods Consecutive patients aged ≥ 65 years who underwent their first implantation of a dual-chamber permanent pacemaker in Beijing Anzhen Hospital from October 2013 to May 2016 were enrolled. Their complete programming and follow-up data were recorded. Follow-up end points included new-onset AF and major adverse cardiovascular and cerebrovascular events. Results Altogether, 322 patients were enrolled, with new-onset AF observed in 79 (24.5%) during their follow-up. Multivariable analysis identified four independent predictors of new-onset AF in elderly patients after pacemaker implantation: hypertension (HR = 3.040, 95% CI: 1.09?3.05, P = 0.00); age (HR = 1.966, 95% CI: 1.57?3.68, P = 0.01); left atrial enlargement (HR = 1.645, 95% CI: 1.05?1.25, P = 0.03); high ventricular pacing rate (HR = 1.137, 95% CI: 1.01?1.06, P = 0.01). Univariable analysis indicated that the CHA2DS2-VASc score was also a risk factor for AF (HR = 1.368, 95% CI: 1.178?1.589, P = 0.002), whereas multivariable regression analysis did not. Kaplan–Meier survival analysis showed that the risk for ischemic stroke was significantly higher in the new-onset AF group than in the non-AF group (P Conclusions Hypertension, age, left atrial enlargement, and high ventricular pacing rate were independent predictors of new-onset AF in elderly patients after implantation of a permanent pacemaker. New-onset AF increased the risk for ischemic stroke.
Objective To retrospectively identify risk factors and the prognosis for new-onset atrial fibrillation (AF) after implantation of dual-chamber pacemakers in elderly patients. Methods Consecutive patients aged ≥ 65 years who underwent their first implantation of a dual-chamber permanent pacemaker in Beijing Anzhen Hospital from October 2013 to May 2016 were enrolled. Their complete programming and follow-up data were recorded. Follow-up end points included new-onset AF and major adverse cardiovascular and cerebrovascular events. Results Altogether, 322 patients were enrolled, with new-onset AF observed in 79 (24.5%) during their follow-up. Multivariable analysis identified four independent predictors of new-onset AF in elderly patients after pacemaker implantation: hypertension (HR = 3.040, 95% CI: 1.09?3.05, P = 0.00); age (HR = 1.966, 95% CI: 1.57?3.68, P = 0.01); left atrial enlargement (HR = 1.645, 95% CI: 1.05?1.25, P = 0.03); high ventricular pacing rate (HR = 1.137, 95% CI: 1.01?1.06, P = 0.01). Univariable analysis indicated that the CHA2DS2-VASc score was also a risk factor for AF (HR = 1.368, 95% CI: 1.178?1.589, P = 0.002), whereas multivariable regression analysis did not. Kaplan–Meier survival analysis showed that the risk for ischemic stroke was significantly higher in the new-onset AF group than in the non-AF group (P Conclusions Hypertension, age, left atrial enlargement, and high ventricular pacing rate were independent predictors of new-onset AF in elderly patients after implantation of a permanent pacemaker. New-onset AF increased the risk for ischemic stroke.
2018, 15(10): 634-638.
doi: 10.11909/j.issn.1671-5411.2018.10.006
Abstract:
None
None
2018, 15(10): 639-643.
doi: 10.11909/j.issn.1671-5411.2018.10.001
Abstract:
None
None
2018, 15(10): 644-646.
doi: 10.11909/j.issn.1671-5411.2018.10.005
Abstract:
None
None
2018, 15(10): 647-648.
doi: 10.11909/j.issn.1671-5411.2018.10.004
Abstract:
None
None
2018, 15(10): 649-652.
doi: 10.11909/j.issn.1671-5411.2018.10.007
Abstract:
None
None
2018, 15(10): 653-656.
doi: 10.11909/j.issn.1671-5411.2018.10.009
Abstract:
None
None
